Evaluation of PD-L1 Expression and Associated Tumor-Squamous Cell Carcinoma

Clinical Cancer Research 22, 704-713 DOI: 10.1158/1078-0432.ccr-15-1543

Citation Report

#	Article	IF	CITATIONS
1	The prognostic value of systemic and local inï¬,ammation in patients with laryngeal squamous cell carcinoma. OncoTargets and Therapy, 2016, Volume 9, 7177-7185.	2.0	58
2	Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, , e277-e282.	3.8	2
3	Basic Overview of Current Immunotherapy Approaches in Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 298-308.	3.8	115
4	T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities. Frontiers in Immunology, 2016, 7, 353.	4.8	77
5	Current understanding of the tumor microenvironment of laryngeal dysplasia and progression to invasive cancer. Current Opinion in Otolaryngology and Head and Neck Surgery, 2016, 24, 121-127.	1.8	18
6	The promise of immunotherapy in head and neck squamous cell carcinoma. Annals of Oncology, 2016, 27, 1675-1685.	1.2	95
7	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non–small Cell Lung Cancer. Journal of Histochemistry and Cytochemistry, 2016, 64, 587-600.	2.5	30
8	Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology, 2016, 48, 574-580.	0.6	59
9	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Scientific Reports, 2016, 6, 36956.	3.3	196
10	Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. Oncolmmunology, 2016, 5, e1181252.	4.6	52
11	Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. Current Treatment Options in Oncology, 2016, 17, 40.	3.0	34
12	High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer, 2017, 104, 1-6.	2.0	144
13	Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma. Oncolmmunology, 2017, 6, e1269047.	4.6	47
14	Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma. Cancer Immunology, Immunotherapy, 2017, 66, 1199-1204.	4.2	25
15	TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?. Head and Neck Pathology, 2017, 11, 354-363.	2.6	67
16	PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. Cancer Research, 2017, 77, 6365-6374.	0.9	77
17	Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. Journal of the American Academy of Dermatology, 2017, 77, 527-533.	1.2	47
18	The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. Oncolmmunology, 2017, 6, e1356148.	4.6	247

#	ARTICLE Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and	IF	CITATIONS
19	Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24,	4.3	530
20	A high ratio of IL-12Rβ2-positive tumor-infiltrating lymphocytes indicates favorable prognosis in laryngeal cancer. Oral Oncology, 2017, 74, 148-156.	1.5	9
21	Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. OncoImmunology, 2017, 6, e1341030.	4.6	36
22	The pattern and clinicopathological correlates of programmed death-ligand 1 expression in cutaneous squamous cell carcinoma. British Journal of Dermatology, 2017, 176, 1354-1356.	1.5	29
23	Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Head and Neck Squamous Cell Carcinoma. Translational Oncology, 2017, 10, 10-16.	3.7	64
24	The tissue distribution and significance of B7-H4 in laryngeal carcinoma. Oncotarget, 2017, 8, 92227-92239.	1.8	10
25	Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma. OncoTargets and Therapy, 2017, Volume 10, 5745-5754.	2.0	14
26	Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Research, 2017, 19, 91.	5.0	90
27	miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression. Oncotarget, 2017, 8, 62143-62153.	1.8	46
28	Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma. Oncotarget, 2017, 8, 92699-92714.	1.8	29
29	PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Oncolmmunology, 2018, 7, e1435226.	4.6	36
30	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Seminars in Cancer Biology, 2018, 52, 228-240.	9.6	314
31	Prognostic significance of tumorâ€infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: A largeâ€scale cohort study. International Journal of Cancer, 2018, 142, 2558-2566.	5.1	73
32	Programmed death ligandâ€1 expression as immunotherapeutic target in sinonasal cancer. Head and Neck, 2018, 40, 818-827.	2.0	39
33	Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, e79-e85.	1.2	32
34	PD-L1 and Other Immunological Diagnosis Tools. , 2018, , 371-385.		2
35	Combined inhibition of JAK1,2/Stat3‑PD‑L1 signaling pathway suppresses the immune escape of castration‑resistant prostate cancer to NK cells in hypoxia. Molecular Medicine Reports, 2018, 17, 8111-8120.	2.4	36
36	IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut, 2018, 67, 320-332.	12.1	381

#	Article	IF	CITATIONS
37	Biological predictors of radiosensitivity in head and neck squamous cell carcinoma. Clinical Oral Investigations, 2018, 22, 189-200.	3.0	29
38	PD-L1 is a positive prognostic factor in squamous cell carcinoma of the nasal vestibule. Rhinology, 2018, 56, 255-260.	1.3	1
39	Significance of PD-L1 Expression in Tongue Cancer Development. International Journal of Medical Sciences, 2018, 15, 1723-1730.	2.5	17
40	From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer. Oral Oncology, 2018, 86, 200-205.	1.5	13
41	Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy. Cancers, 2018, 10, 374.	3.7	19
42	The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncology, 2018, 86, 81-90.	1.5	95
43	Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment. Head and Neck, 2018, 40, 2007-2019.	2.0	47
44	Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatric Drugs, 2018, 20, 395-408.	3.1	76
45	Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Pediatric Blood and Cancer, 2018, 65, e27313.	1.5	11
46	Microbial biomarkers for immune checkpoint blockade therapy against cancer. Journal of Gastroenterology, 2018, 53, 999-1005.	5.1	15
47	Preâ€ŧreatment <scp>CD</scp> 8 ⁺ tumourâ€infiltrating lymphocyte density predicts distant metastasis after definitive treatment in patients with stage <scp>III</scp> / <scp>IV</scp> hypopharyngeal squamous cell carcinoma. Clinical Otolaryngology, 2018, 43, 1312-1320.	1.2	27
48	PDâ€L1 Expression and Tumorâ€Infiltrating Lymphocytes in Highâ€Risk and Metastatic Cutaneous Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2019, 160, 93-99.	1.9	23
49	Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis. Aging, 2019, 11, 501-522.	3.1	25
50	Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1443-1454.	4.2	13
51	Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting. Frontiers in Oncology, 2019, 9, 827.	2.8	126
52	<p>Clinical relevance and significance of programmed death-ligand 1 expression, tumor-infiltrating lymphocytes, and p16 status in sinonasal squamous cell carcinoma</p> . Cancer Management and Research, 2019, Volume 11, 4335-4345.	1.9	23
53	Identification of miRâ€145â€5p entered Competing Endogenous RNA Network in Laryngeal Squamous Cell Carcinoma. Proteomics, 2019, 19, e1900020.	2.2	15
54	High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations. International Journal of Molecular Sciences, 2019, 20, 2823.	4.1	39

#	Article	IF	CITATIONS
55	Assessment of tumor-associated immune cells in laryngeal squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1761-1772.	2.5	22
56	Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. Journal of Clinical Pathology, 2019, 72, 542-549.	2.0	26
57	PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection. Journal of Cancer, 2019, 10, 937-948.	2.5	39
58	Expression of vimentin (VIM) and metastasis-associated 1 (MTA1) protein in laryngeal squamous cell carcinoma are associated with prognostic outcome of patients. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2019, 40, 487-493.	1.3	8
59	SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Journal of Translational Medicine, 2019, 17, 429.	4.4	5
60	PD-L1 Detection—Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology. American Journal of Dermatopathology, 2019, 41, 539-565.	0.6	8
61	Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms. European Journal of Cardio-thoracic Surgery, 2019, 55, 691-698.	1.4	12
62	Molecular and immunologic analysis of laryngeal squamous cell carcinoma in smokers and non-smokers. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2019, 40, 213-217.	1.3	9
63	The value of immunotherapy in head and neck cancer. Expert Opinion on Biological Therapy, 2019, 19, 35-43.	3.1	14
64	Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma. Oral Oncology, 2020, 102, 104560.	1.5	21
65	Tumor Infiltrating Lymphocytes and CD8+ T Cell Subsets as Prognostic Markers in Patients with Surgically Treated Laryngeal Squamous Cell Carcinoma. Head and Neck Pathology, 2020, 14, 689-700.	2.6	19
66	The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer. Frontiers in Immunology, 2020, 11, 1721.	4.8	61
67	Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2020, 21, 7032.	4.1	20
68	Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. Molecular Therapy - Nucleic Acids, 2020, 22, 298-309.	5.1	181
69	Postoperative radiotherapy for laryngeal cancer. The prognostic role of programmed death-ligand 1: An immune microenvironment-based cluster analysis. Pathology Research and Practice, 2020, 216, 153120.	2.3	12
70	An increase of CD8+ T cell infiltration following recurrence is a good prognosticator in HNSCC. Scientific Reports, 2020, 10, 20059.	3.3	34
71	<role after="" and="" association="" cancer<="" expression="" favourable="" glut-1="" hypopharyngeal="" in="" of="" overall="" p="" pd-l1="" radiotherapy="" survival="" the="" upregulation="" with="">. OncoTargets and Therapy, 2020, Volume 13, 11221-11235.</role>	2.0	11
72	<p>Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma</p> . Cancer Management and Research, 2020, Volume 12, 5893-5902.	1.9	13

#	Article	IF	CITATIONS
73	Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis. BMC Clinical Pathology, 2020, 13, 2632010X2096484.	1.7	4
74	CD8+ Tumour-Infiltrating Lymphocytes and Tumour Microenvironment Immune Types as Biomarkers for Immunotherapy in Sinonasal Intestinal-Type Adenocarcinoma. Vaccines, 2020, 8, 202.	4.4	15
75	Low expression of miR-20b-5p indicates favorable prognosis in laryngeal squamous cell carcinoma, especially in patients with non-infiltrated regional lymph nodes. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2020, 41, 102563.	1.3	7
76	Prognostic role of programmed death ligand 1 (PD-L1) and the immune microenvironment in laryngeal carcinoma. Oral Oncology, 2020, 108, 104836.	1.5	22
77	Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer. Frontiers in Oncology, 2020, 10, 268.	2.8	68
78	Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis. Scientific Reports, 2020, 10, 2662.	3.3	14
79	Biomarkers for immunotherapy response in head and neck cancer. Cancer Treatment Reviews, 2020, 84, 101977.	7.7	153
80	Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression. Head and Neck Pathology, 2020, 14, 951-965.	2.6	11
81	Transcriptomic and Immunophenotypic Characterization of Tumor Immune Microenvironment in Squamous Cell Carcinoma of the Oral Tongue. Head and Neck Pathology, 2021, 15, 509-522.	2.6	7
82	Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer. Annals of Diagnostic Pathology, 2021, 50, 151657.	1.3	21
83	Bioinformatics analysis identifies COL1A1, THBS2 and SPP1 as potential predictors of patient prognosis and immunotherapy response in gastric cancer. Bioscience Reports, 2021, 41, .	2.4	16
84	The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy. Frontiers in Immunology, 2020, 11, 617583.	4.8	20
85	PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling. International Journal of Oral Science, 2021, 13, 8.	8.6	15
86	PD-L1 expression in recurrent head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 2022, 279, 343-351.	1.6	6
87	Tumor-Infiltrating Lymphocytes in the Tumor Microenvironment of Laryngeal Squamous Cell Carcinoma: Systematic Review and Meta-Analysis. Biomedicines, 2021, 9, 486.	3.2	28
88	TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 665265.	3.7	6
89	Potential prognostic value of PD-L1 and NKG2A expression in Indonesian patients with skin nodular melanoma. BMC Research Notes, 2021, 14, 206.	1.4	1
90	Histologic evaluation of host immune microenvironment and its prognostic significance in oral tongue squamous cell carcinoma: a comparative study on lymphocytic host response (LHR) and tumor infiltrating lymphocytes (TILs). Pathology Research and Practice, 2021, 228, 153473.	2.3	4

#	Article	IF	CITATIONS
91	Characterization of the Immune Cell Infiltration Profile in Pancreatic Carcinoma to Aid in Immunotherapy. Frontiers in Oncology, 2021, 11, 677609.	2.8	7
92	Prognostic and Therapeutic Implications of Immune Classification by CD8+ Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Sinonasal Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2021, 22, 6926.	4.1	12
93	An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. Frontiers in Pharmacology, 2021, 12, 707930.	3.5	12
94	Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer. Biomolecules, 2021, 11, 970.	4.0	4
95	Gene Model Related to m6A Predicts the Prognostic Effect of Immune Infiltration on Head and Neck Squamous Cell Carcinoma. Journal of Oncology, 2021, 2021, 1-11.	1.3	1
96	Identification of Immune Cell Infiltration Landscape and Their Prognostic Significance in Uveal Melanoma. Frontiers in Cell and Developmental Biology, 2021, 9, 713569.	3.7	12
97	Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis. Molecules, 2021, 26, 4848.	3.8	5
98	YAP/STAT3 promotes the immune escape of larynx carcinoma by activating VEGFR1-TGFÎ ² signaling to facilitate PD-L1 expression in M2-like TAMs. Experimental Cell Research, 2021, 405, 112655.	2.6	4
99	High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments. Biomedicines, 2021, 9, 1132.	3.2	7
100	Biomarkers of laryngeal squamous cell carcinoma: a review. Annals of Diagnostic Pathology, 2021, 54, 151787.	1.3	15
101	Immunologic "Cold―Squamous Cell Carcinomas of the Head and Neck Are Associated With an Unfavorable Prognosis. Frontiers in Medicine, 2021, 8, 622330.	2.6	23
102	Infiltrating immune cells are associated with radiosensitivity and favorable survival in head and neck cancer treated with definitive radiotherapy. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2020, 129, 612-620.	0.4	10
103	A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer. Medical Science Monitor, 2020, 26, e925583.	1.1	14
104	Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0179536.	2.5	34
105	Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping. Oncotarget, 2017, 8, 46756-46768.	1.8	41
106	Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma. Oncotarget, 2017, 8, 66178-66194.	1.8	50
107	Towards tumor immunodiagnostics. Annals of Translational Medicine, 2016, 4, 263-263.	1.7	11
108	PD-L1 as a biomarker in NSCLC: challenges and future directions. Annals of Translational Medicine,	1.7	35

#	Article	IF	CITATIONS
109	Quantitative analysis and study of the mRNA expression levels of apoptotic genes BCL2, BAX and BCL2L12 in the articular cartilage of an animal model of osteoarthritis. Annals of Translational Medicine, 2018, 6, 243-243.	1.7	10
110	Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer. Annals of Translational Medicine, 2018, 6, 241-241.	1.7	90
111	Alternative Splicing Detection Tool—a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis. Annals of Translational Medicine, 2018, 6, 244-244.	1.7	17
112	PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. Anticancer Research, 2017, 37, 1417-1424.	1.1	51
113	Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling. International Journal of Oncology, 2020, 56, 909-920.	3.3	13
114	Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Translational Lung Cancer Research, 2015, 4, 743-51.	2.8	31
115	Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images. Journal of Pathology Informatics, 2019, 10, 24.	1.7	70
116	Effect of Programmed Death-Ligand 1 in Cancer-Associated Fibroblasts on Advanced Laryngeal Squamous Cell Carcinoma. Technology in Cancer Research and Treatment, 2021, 20, 153303382110464.	1.9	0
117	Identification of novel subtypes based on ssGSEA in immuneâ€related prognostic signature for tongue squamous cell carcinoma. Cancer Medicine, 2021, 10, 8693-8707.	2.8	21
118	Potential role of immune cell genetic variants associated with tumor microenvironment response in laryngeal squamous cell carcinoma (LSCC) in terms of clinicopathological features. Pathology Research and Practice, 2021, 228, 153665.	2.3	1
119	Pembrolizumab in the first-line treatment of advanced head and neck cancer. Expert Review of Anticancer Therapy, 2021, 21, 1321-1331.	2.4	11
120	Anatomopathologie. , 2019, , 31-46.		Ο
121	Baş Boyun Skuamöz Hücreli Kanserlerde Tümör İnfiltre Edici Lenfosit Yoğunluğunun Histopatolojik Parametrelerle Karşılaştırılması ve Prognoz Üzerine Etkisi. Sisli Etfal Hastanesi Tip Bulteni, 2019, 54, 438-443.	0.3	0
122	Relationship between local and systemic inflammatory response and prognosis in laryngeal squamous cell carcinoma. İstanbul Kuzey Klinikleri, 2019, 7, 180-184.	0.3	3
123	PD-L1 and CD8-Tumor-Infiltrating Lymphocytes Expression in Laryngeal Squamous Cell Carcinoma. ARS Medica Tomitana, 2020, 26, 137-144.	0.1	0
124	The Role of B Cells in Head and Neck Cancer. Cancers, 2021, 13, 5383.	3.7	10
125	PD-L1 and survival in oral cavity squamous cell carcinoma. Parodontologiya, 2020, 25, 287-294.	0.6	1
126	Characterization of epithelial cells, connective tissue cells and immune cells in human upper airway mucosa by immunofluorescence multichannel image cytometry: a pilot study. Histochemistry and Cell Biology 2021, 155, 405-421	1.7	7

#	Article	IF	CITATIONS
127	CD8 + T Cell Infiltration Predicts Chemoradiosensitivity in Nasopharyngeal or Oropharyngeal Cancer. Laryngoscope, 2021, 131, E1179-E1189.	2.0	9
128	Vaccine-Based Immunotherapy for Head and Neck Cancers. Cancers, 2021, 13, 6041.	3.7	16
129	Tumor budding to investigate local invasion, metastasis and prognosis in temporal bone squamous cell carcinoma. Pathology Research and Practice, 2022, 229, 153719.	2.3	8
130	Pyroptosis-related gene mediated modification patterns and immune cell infiltration landscapes in cutaneous melanoma to aid immunotherapy. Aging, 2021, 13, 24379-24401.	3.1	12
131	Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group. British Journal of Cancer, 2022, 126, 1589-1594.	6.4	22
132	Characterization of epigenomic alterations in HPV16+ head and neck squamous cell carcinomas. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.EPI-21-0922-A.2021.	2.5	6
133	Characteristics of the Immune Cell Infiltration Landscape in Gastric Cancer to Assistant Immunotherapy. Frontiers in Genetics, 2021, 12, 793628.	2.3	8
134	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. Molecular Diagnosis and Therapy, 2022, , 1.	3.8	2
135	Comprehensive analysis of immune cell infiltration and significant genes in head and neck squamous cell carcinoma. Oral Oncology, 2022, 126, 105755.	1.5	5
136	Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. Frontiers in Oncology, 2022, 12, 847350.	2.8	6
137	The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma. Journal of Liver Cancer, 2022, 22, 40-50.	1.1	0
138	Development and Validation of an Immune-Related Signature for the Prediction of Recurrence Risk of Patients With Laryngeal Cancer. Frontiers in Oncology, 2021, 11, 683915.	2.8	8
139	Autoimmunity regulation within the tumor microenvironment. , 2022, , 51-71.		0
141	Association of immune response with overall and disease-free survival in laryngeal squamous cell carcinomas. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2022, 43, 103477.	1.3	0
142	Tumor Infiltrating Lymphocytes are Prognostic Factors and Can Be Markers of Sensitivity to Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma. Asian Pacific Journal of Cancer Prevention, 2022, 23, 1271-1278.	1.2	7
143	Understanding the tumor microenvironment in head and neck squamous cell carcinoma. Clinical and Translational Immunology, 2022, 11, .	3.8	10
144	The Immune Cell Infiltration Patterns and Characterization Score in Bladder Cancer to Identify Prognosis. Frontiers in Genetics, 0, 13, .	2.3	3
145	Moesin Serves as Scaffold Protein for PD-L1 in Human Uterine Cervical Squamous Carcinoma Cells. Journal of Clinical Medicine, 2022, 11, 3830.	2.4	5

#	Article	IF	CITATIONS
146	The Multi-Omics Landscape and Clinical Relevance of the Immunological Signature of Phagocytosis Regulators: Implications for Risk Classification and Frontline Therapies in Skin Cutaneous Melanoma. Cancers, 2022, 14, 3582.	3.7	0
147	PD-L1 and the Clinical Outcomes of Ovarian Cancer: Meta-Analysis and Bioinformatical Analysis. Asian Pacific Journal of Cancer Prevention, 2022, 23, 2285-2290.	1.2	0
148	Core immune cell infiltration signatures identify molecular subtypes and promote precise checkpoint immunotherapy in cutaneous melanoma. Frontiers in Immunology, 0, 13, .	4.8	8
149	Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy. Cancer Research, 2022, 82, 3532-3548.	0.9	14
150	During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes. Cell Reports, 2022, 40, 111171.	6.4	22
151	Biomarkers for Immunotherapy in Poorly Differentiated Sinonasal Tumors. Biomedicines, 2022, 10, 2205.	3.2	5
152	Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer. Frontiers in Immunology, 0, 13, .	4.8	5
153	IncRNAs AC156455.1 and AC104532.2 as Biomarkers for Diagnosis and Prognosis in Colorectal Cancer. Disease Markers, 2022, 2022, 1-13.	1.3	2
155	Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab. Cancer Management and Research, 0, Volume 14, 3293-3302.	1.9	2
156	A novel prognostic model related to oxidative stress for treatment prediction in lung adenocarcinoma. Frontiers in Oncology, 0, 13, .	2.8	2
157	Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer. Strahlentherapie Und Onkologie, 0, , .	2.0	0
158	PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers. Journal of Clinical Medicine, 2023, 12, 2033.	2.4	1
160	Immunological role and prognostic value of the SKA family in pan-cancer analysis. Frontiers in Immunology, 0, 14, .	4.8	0
162	The Histological Background of Recurrence in Laryngeal Squamous Cell Carcinoma: An Insight into the Modifications of Tumor Microenvironment. Cancers, 2023, 15, 3259.	3.7	1
163	Identification and validation of m6A-GPI signatures as a novel prognostic model for colorectal cancer. Frontiers in Oncology, 0, 13, .	2.8	0
165	Exploration of novel clusters and prognostic value of immune‑related signatures and identify HAMP as hub gene in colorectal cancer. Oncology Letters, 2023, 26, .	1.8	1
166	Programmed death-ligand 1 and tumor-infiltrating lymphocytes (TILs) – low TIL density may predict poorer long-term prognosis in T1 laryngeal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 0, , .	2.8	0
167	A predictive model of immune infiltration and prognosis of head and neck squamous cell carcinoma based on cell adhesion-related genes: including molecular biological validation. Frontiers in Immunology, 0, 14, .	4.8	2

#	Article	IF	CITATIONS
168	Integrated bioinformatics and validation reveal SOX12 as potential biomarker in colon adenocarcinoma based on an immune infiltration-related ceRNA network. Journal of Cancer Research and Clinical Oncology, 2023, 149, 15737-15762.	2.5	0
169	The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1. Japanese Journal of Radiology, 0, , .	2.4	0
171	Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncology, 2024, 149, 106664.	1.5	0
172	Construction and validation of a colon cancer prognostic model based on tumor mutation burden-related genes. Scientific Reports, 2024, 14, .	3.3	0
173	TG468: a text graph convolutional network for predicting clinical response to immune checkpoint inhibitor therapy. Briefings in Bioinformatics, 2024, 25, .	6.5	0